Attached files
| file | filename |
|---|---|
| EX-12.1 - RATIO OF EARNINGS TO FIXED CHARGES - PDL BIOPHARMA, INC. | pdli1231201510-kex121.htm |
| EX-10.71 - SCHEDULE OF AMENDMENTS TO OMITTED CREDIT AGREEMENTS - PDL BIOPHARMA, INC. | pdli1231201510-kex1071.htm |
| EX-21.1 - SUBSIDIARIES OF THE REGISTRANT - PDL BIOPHARMA, INC. | pdli1231201510-kex211.htm |
| EX-32.1 - CERTIFICATION - PDL BIOPHARMA, INC. | pdli1231201510-kex321.htm |
| EX-31.2 - CERTIFICATION - PDL BIOPHARMA, INC. | pdli1231201510-kex312.htm |
| EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - PDL BIOPHARMA, INC. | pdli1231201510-kex231.htm |
| 10-K - 10-K - PDL BIOPHARMA, INC. | pdli1231201510-kdoc.htm |
| EX-31.1 - CERTIFICATION - PDL BIOPHARMA, INC. | pdli1231201510-kex311.htm |
Exhibit 23.2
CONSENT OF ERNST & YOUNG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
(1) Registration Statement (Form S-3 no. 333-36708) of PDL BioPharma, Inc.,
(2) Registration Statement (Form S-3 No. 333-122760) of PDL BioPharma, Inc.,
(3) Registration Statement (Form S-3 No. 333-123958) of PDL BioPharma, Inc.,
(4) Registration Statement (Form S-3 No. 333-128644) of PDL BioPharma, Inc.,
(5) Registration Statement (Form S-3ASR No. 333-189536) of PDL BioPharma, Inc.,
(6) | Registration Statement (Form S-8 No. 333-87957) pertaining to the 1999 Stock Option Plan and 1999 Nonstatutory Stock Option Plan of PDL BioPharma, Inc., |
(7) | Registration Statement (Form S-8 No. 333-68314) pertaining to the 1999 Stock Option Plan and 1999 Nonstatutory Stock Option Plan of PDL BioPharma, Inc., |
(8) | Registration Statement (Form S-8 No. 333-104170) pertaining to the 1999 Nonstatutory Stock Option Plan of PDL BioPharma, Inc., |
(9) | Registration Statement (Form S-8 No. 333-125906) pertaining to the 2005 Equity Incentive Plan of PDL BioPharma, Inc., and |
(10) Registration Statement (Form S-8 No. 333-145262) pertaining to the 2005 Equity Incentive Plan.
of our report dated March 3, 2014, with respect to the consolidated financial statements of income, comprehensive income, stockholders' equity (deficit) and cash flows of PDL BioPharma, Inc. for the year ended December 31, 2013, included in this Annual Report (Form 10-K) for the year ended December 31, 2015.
/s/ ERNST & YOUNG LLP
Redwood City, California
February 22, 2016